109 related articles for article (PubMed ID: 17210689)
1. Dominant-negative Fas mutation is reversed by down-expression of c-FLIP.
Bénéteau M; Daburon S; Moreau JF; Taupin JL; Legembre P
Cancer Res; 2007 Jan; 67(1):108-15. PubMed ID: 17210689
[TBL] [Abstract][Full Text] [Related]
2. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis.
Stel AJ; Ten Cate B; Jacobs S; Kok JW; Spierings DC; Dondorff M; Helfrich W; Kluin-Nelemans HC; de Leij LF; Withoff S; Kroesen BJ
J Immunol; 2007 Feb; 178(4):2287-95. PubMed ID: 17277134
[TBL] [Abstract][Full Text] [Related]
3. Resistance to Fas-mediated cell death in BeWo and NJG choriocarcinoma cell lines: implications in immune privilege.
Rajashekhar G; Loganath A; Roy AC; Mongelli JM
Gynecol Oncol; 2003 Oct; 91(1):89-100. PubMed ID: 14529667
[TBL] [Abstract][Full Text] [Related]
4. The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation.
Wang L; Azad N; Kongkaneramit L; Chen F; Lu Y; Jiang BH; Rojanasakul Y
J Immunol; 2008 Mar; 180(5):3072-80. PubMed ID: 18292530
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.
Rao-Bindal K; Koshkina NV; Stewart J; Kleinerman ES
Curr Cancer Drug Targets; 2013 May; 13(4):411-22. PubMed ID: 23410027
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic transplantation, Fas signaling, and dysregulation of hepcidin.
Li X; Xu F; Karoopongse E; Marcondes AM; Lee K; Kowdley KV; Miao CH; Trobridge GD; Campbell JS; Deeg HJ
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1210-9. PubMed ID: 23707854
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of caspase-8/FLICE processing and activation upon Fas stimulation with novel antibodies directed against a cleavage site for caspase-8 and its substrate, FLICE-like inhibitory protein (FLIP).
Niikura Y; Nonaka T; Imajoh-Ohmi S
J Biochem; 2002 Jul; 132(1):53-62. PubMed ID: 12097160
[TBL] [Abstract][Full Text] [Related]
8. Rapid up-regulation of c-FLIP expression by BCR signaling through the PI3K/Akt pathway inhibits simultaneously induced Fas-mediated apoptosis in murine B lymphocytes.
Moriyama H; Yonehara S
Immunol Lett; 2007 Mar; 109(1):36-46. PubMed ID: 17275920
[TBL] [Abstract][Full Text] [Related]
9. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.
Fulda S; Meyer E; Debatin KM
Cancer Res; 2000 Jul; 60(14):3947-56. PubMed ID: 10919673
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP).
Suhara T; Mano T; Oliveira BE; Walsh K
Circ Res; 2001 Jul; 89(1):13-9. PubMed ID: 11440972
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of Fas-associated death domain-like IL-1-converting enzyme (FLICE)-inhibitory protein induces resistance to Fas-mediated apoptosis in activated mast cells.
Yoshikawa H; Nakajima Y; Tasaka K
J Immunol; 2000 Dec; 165(11):6262-9. PubMed ID: 11086061
[TBL] [Abstract][Full Text] [Related]
12. Fas aggregation does not correlate with Fas-mediated apoptosis.
Lee Y; Shacter E
J Immunol; 2001 Jul; 167(1):82-9. PubMed ID: 11418635
[TBL] [Abstract][Full Text] [Related]
13. Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells.
Hennino A; Berard M; Casamayor-Pallejà M; Krammer PH; Defrance T
J Immunol; 2000 Sep; 165(6):3023-30. PubMed ID: 10975811
[TBL] [Abstract][Full Text] [Related]
14. Cutting edge: SDS-stable Fas microaggregates: an early event of Fas activation occurring with agonistic anti-Fas antibody but not with Fas ligand.
Legembre P; Beneteau M; Daburon S; Moreau JF; Taupin JL
J Immunol; 2003 Dec; 171(11):5659-62. PubMed ID: 14634070
[TBL] [Abstract][Full Text] [Related]
15. Cholangiocarcinomas express Fas ligand and disable the Fas receptor.
Que FG; Phan VA; Phan VH; Celli A; Batts K; LaRusso NF; Gores GJ
Hepatology; 1999 Dec; 30(6):1398-404. PubMed ID: 10573518
[TBL] [Abstract][Full Text] [Related]
16. Phosphatidylinositol 3-kinase/Akt positively regulates Fas (CD95)-mediated apoptosis in epidermal Cl41 cells.
Lu B; Wang L; Stehlik C; Medan D; Huang C; Hu S; Chen F; Shi X; Rojanasakul Y
J Immunol; 2006 Jun; 176(11):6785-93. PubMed ID: 16709838
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation and function of the Fas/Fas ligand system in human trophoblast cells.
Aschkenazi S; Straszewski S; Verwer KM; Foellmer H; Rutherford T; Mor G
Biol Reprod; 2002 Jun; 66(6):1853-61. PubMed ID: 12021072
[TBL] [Abstract][Full Text] [Related]
18. Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation.
Yang BF; Xiao C; Li H; Yang SJ
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1245-51. PubMed ID: 17973862
[TBL] [Abstract][Full Text] [Related]
19. Magnetic nanoparticle-mediated gene therapy to induce Fas apoptosis pathway in breast cancer.
Basoglu H; Goncu B; Akbas F
Cancer Gene Ther; 2018 Jun; 25(5-6):141-147. PubMed ID: 29593359
[TBL] [Abstract][Full Text] [Related]
20. CD95 stimulation results in the formation of a novel death effector domain protein-containing complex.
Lavrik IN; Mock T; Golks A; Hoffmann JC; Baumann S; Krammer PH
J Biol Chem; 2008 Sep; 283(39):26401-8. PubMed ID: 18635548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
